Doximity faces flat growth, competitive pressure, and overvaluation, making it a potential short with a $45 target. Click ...

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.

Q1 2025 Earnings Call Transcript May 7, 2025 Operator: Hello and welcome to Mirum Pharmaceuticals Reports First Quarter 2025 ...

Q2 2025 Earnings Call Transcript May 12, 2025 Arrowhead Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $2 ...

Danish pharmaceutical company Novo Nordisk has signed a collaboration deal with U.S. biotech Septerna that will see the two companies develop pills to treat obesity, type 2 diabetes and other ...

Kirkpatrick noted that the company continues to work on the development of its lead product, PF614, an extended-release oxycodone to treat severe pain, as well as its combination product, PF614-MPAR, ...

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) were trading at $30.25, down $5.60, or 15%, on word of the delay of data from the phase III X-tole2 trial with azetukalner in focal onset seizures ...

The Pasadena, Calif., biotechnology company, which uses RNA interference to develop treatments, said Monday it recorded a profit of $370.4 million, or $2.75 a share, during the fiscal second quarter, ...

Merck is facing an awkward encore as one of the worst-performing blue chip stocks in 2025, sliding 23.3% year-to-date.

Collegium Pharmaceutical (COLL) said it has entered into an accelerated share repurchase agreement ((ASR)) with Jefferies to buy back $25 million of its stock.

The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR ...

Mira Pharmaceuticals to acquire SKNY in a stock-based deal valuing both firms near $30 million each, backed by third-party ...